Altimmune, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALT Nasdaq 2830 altimmune.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Altimmune, Inc.

Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report? - Sep 11th, 2026 9:30 am
Altimmune’s (ALT) Three Liver Trials Move Forward At Once - Sep 7th, 2026 8:27 pm
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - Sep 3rd, 2026 6:00 am
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger? - Aug 19th, 2026 8:55 am
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus - Aug 19th, 2026 8:54 am
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus - Aug 14th, 2026 8:14 am
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus - Aug 13th, 2026 10:14 am
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ... - Aug 12th, 2026 5:03 pm
Altimmune Q2 Earnings Call Highlights - Aug 12th, 2026 8:05 am
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA - Aug 12th, 2026 6:54 am
Altimmune, Inc. Q2 2026 Earnings Call Summary - Aug 12th, 2026 6:30 am
Altimmune Announces Second Quarter 2026 Financial Results and Business Update - Aug 12th, 2026 5:30 am
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema - Aug 11th, 2026 9:15 am
PBYI Q2 Earnings & Sales Beat Estimates, 2026 Guidance Raised - Aug 7th, 2026 9:15 am
Perrigo Stock Rises 23% as Q2 Earnings & Sales Beat Estimates - Aug 6th, 2026 12:24 pm
Immunovant's Q1 Loss Wider Than Expected, Pipeline in Progress - Aug 6th, 2026 9:22 am
SYRE's Q2 Loss Narrower Than Expected, Pipeline Progresses - Aug 5th, 2026 9:08 am
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026 - Aug 5th, 2026 6:00 am
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH - Aug 3rd, 2026 6:00 am
FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data - Jul 29th, 2026 5:00 am